Inactive Instrument

Highlights Boston Therapeutics, Inc. Other OTC

Equities

BTHE

US1011501004

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Nanomix Corporation Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-07	CI
Nanomix Appoints Finance Veteran Chris Hetterly as Chief Financial Officer	23-01-25	GL
Nanomix Appoints Finance Veteran Chris Hetterly as Chief Financial Officer	23-01-25	GL
Nanomix Corporation Appoints Christopher R. Hetterly as Chief Financial Officer	23-01-25	CI
Nanomix Corporation Enters into Distribution Agreement for the eLab System with Gepa Srl in Italy	22-11-29	CI
Nanomix Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Nanomix Corporation Enters into an Exclusive Veterinary Distribution Agreement for the eLab System with Woodley Equipment Company, Ltd	22-11-09	CI
Nanomix Corporation Enters into Multi-Country Distribution Agreement for the Elab System with Mast Group Limited	22-11-04	CI
Nanomix Corporation Announces Distribution Agreement with Diaclinic SpA	22-10-20	CI
Nanomix Enters into Distribution Agreement for the Elab System and Future New Products with Ips Genomix S.A.L. in the Middle East	22-09-12	CI
Nanomix Corporation Announces Agreement with Mobility Health to Co-Develop a Lab Development Test for Evaluating Levels of COVID-19 Circulating Antibodies	22-09-02	CI
Nanomix Enters into Distribution Agreement for the Elab System and Future New Products with Bioasia Pte Ltd in Singapore	22-08-23	CI
Nanomix Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-15	CI
Nanomix Corporation Announces Distribution Agreement for the eLab System with Biotron Ltd. in Israel	22-07-21	CI
Nanomix Corporation Initiates New Clinical Study for the eLab S1 Panel	22-06-22	CI
Nanomix Corporation Receives IVDR Certification for the eLab Analyzer	22-06-14	CI
Nanomix Granted Ce Mark for Elab S1 Assay Panel for Whole Blood Samples	22-05-26	CI
Nanomix Corporation Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-17	CI
Nanomix Announces UK MHRA Registration for New Point of Care System	21-12-08	CI
Nanomix Corporation Submits Emergency Use Authorization Application for its Rapid Point-of-Care Antigen Panel to Detect COVID-19	21-12-01	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Boston Therapeutics, Inc. Other OTC

Equities

BTHE

US1011501004

Highlights

Filters